Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Palatin Technologies, Inc. ( NYSE: PTN) Q4 2024 Incomes Teleconference October 1, 2024 11:00 AM ET

Business Individuals

Carl Spana – Ceo and President
Stephen Wills – Chief Financial Officer, Chief Operating Officer, Treasurer and Secretary

Teleconference Individuals

Joe Pantginis – H.C. Wainwright
John Newman – Canaccord Genuity

Operator

Greetings. Invite to Palatin’s 4th Quarter and Fiscal Year-End 2024 Operating Outcomes Teleconference. At this time, all individuals remain in a listen-only mode. A question-and-answer session will follow the official discussion. [Operator Instructions] As a suggestion, this teleconference is being taped.

Before we start our remarks, I wish to advise you that declarations made by Palatin are not historic realities and might be positive declarations. These declarations are based upon presumptions that might or might not show to be precise which the real outcomes might vary materially from those prepared for due to the range of dangers and unpredictabilities talked about in the business’s newest filings with the Securities and Exchange Commission. Please think about such dangers and unpredictabilities thoroughly in examining these positive declarations by Palatin’s potential customers.

Now I wish to turn the call over to our host Dr. Carl Spana, President and Ceo of Palatin. Please go on.

Carl Spana

Thank you. Excellent early morning and welcome to the Palatin year-end financial 2024 call. I’m Dr. Carl Spana, CEO and President of Palatin. With me on the call today is Steve Wills, Palatin’s Chief Financial Officer and Chief Operating Officer.

I’ll now turn the call over to Steve and he’ll provide the monetary upgrade.

Stephen Wills

Thank you, Carl. Excellent early morning, excellent afternoon, everybody. Before evaluating the monetary outcomes, I have a couple of other business products to highlight. Relating to Vyleesi, bremelanotide injection, an industrial item, Palatin established for hypoactive libido condition or HSDD.